| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0735-1097(01)01662-X |
| P698 | PubMed publication ID | 11738308 |
| P2093 | author name string | P Rosin | |
| A M Zeiher | |||
| W Auch-Schwelk | |||
| S Fichtlscherer | |||
| V Schächinger | |||
| D H Walter | |||
| M B Britten | |||
| P2860 | cites work | Effect of statin therapy on restenosis after coronary stent implantation | Q73665593 |
| Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease | Q74232819 | ||
| Statin trials and goals of cholesterol-lowering therapy | Q74519752 | ||
| Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation | Q77120486 | ||
| Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina | Q77178269 | ||
| Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction | Q77483711 | ||
| HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis | Q77700153 | ||
| Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial | Q77933067 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men | Q29619308 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Current perspectives on statins | Q33818381 | ||
| Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial | Q33940282 | ||
| Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group | Q34064191 | ||
| C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction | Q40857092 | ||
| Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial | Q41735567 | ||
| Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses | Q47713328 | ||
| Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. | Q50866439 | ||
| Novel inflammatory markers of coronary risk: theory versus practice. | Q54332281 | ||
| Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty | Q58230324 | ||
| Enhanced Inflammatory Response to Coronary Angioplasty in Patients With Severe Unstable Angina | Q58230329 | ||
| The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina | Q58230388 | ||
| Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions | Q71745417 | ||
| Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction | Q71807599 | ||
| Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment | Q72571519 | ||
| Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial | Q72791714 | ||
| Serum levels of circulating adhesion molecules after coronary angioplasty | Q73142842 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2006-2012 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation | |
| P478 | volume | 38 |
| Q36337932 | Anti-inflammatory effects of statins: clinical evidence and basic mechanisms |
| Q73580828 | Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting |
| Q73739828 | C-reactive protein and coronary events following percutaneous coronary angioplasty |
| Q51729364 | C-reactive protein and myocardial infarction during percutaneous coronary intervention. |
| Q47668949 | C-reactive protein plasma levels but not factor VII activity predict clinical outcome in patients undergoing elective coronary intervention |
| Q42380274 | Early Statins after Intravenous or Endovascular Recanalization Is Beneficial Regardless of Timing, Intensity, and Stroke Mechanism. |
| Q44160619 | Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events |
| Q44917344 | Effect of statins and white blood cell count on mortality in patients with ischemic left ventricular dysfunction undergoing percutaneous coronary intervention. |
| Q44575008 | Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits |
| Q35077214 | Effects of statins on inflammation in patients with acute and chronic coronary syndromes |
| Q34677026 | HbA1c in Patients with Polycystic Ovary Syndrome: A Potential Marker of Inflammation |
| Q22241929 | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association |
| Q35575681 | Percutaneous coronary intervention: historical perspectives, current status, and future directions |
| Q44532772 | Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study |
| Q35584631 | Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease |
| Q73739845 | Restenosis after coronary intervention: narrowing C-reactive protein's prognostic potential? |
| Q44133509 | Statin treatment following coronary artery stenting and one-year survival |
| Q37786646 | Stents and statins: history, clinical outcomes and mechanisms |
| Q90568044 | The Preoperative Inflammatory Status Affects the Clinical Outcome in Cardiac Surgery |
| Q46561053 | The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention. |
| Q46863161 | Underrecognized peripheral arterial disease in patients with acute coronary syndrome: prevalence of traditional and emergent cardiovascular risk factors |
| Q73937444 | Value of C-reactive protein in patients with stable angina pectoris, coronary narrowing (30% to 70%), and normal fractional flow reserve |
| Q37597742 | Vitamin D and acute myocardial infarction |
Search more.